Irodalom:
1. O’Neill LA: Bacteria fight back against toll-like receptors. Nat Med 2008, 14, 370-372.
2. Hunt KA et al: Newly identified genetic risk variants for coeliac disease related to the immune response.
Nat Genet 2008, 40,395-402.
3. Schumann M et al: Mechanism of epithelial translocation of the alpha(2)-gliadin 33-mer in coeliac
sprue. Gut, 2008, 57, 747-754.
4. Lammers KM et al: Gliadine induces an increase in intestinal permeability and zonulin release by binding
to the chemokine receptor CXCR3. Gastroenterology, 2008, 135, 194-204.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 474
Egyéb 475
5. Szebeni B et al: Increased mucosal expression of Toll-like receptor (TLR) 2 and TLR4 in coeliac disease.
J Pediatr Gastroenterol Nutr, 2007, 45, 187-193.
6. Bhagat G et al: Small intestinal CD8+TCR γσ+NKG2A+ intraepithelial lymphocytes have attributes of
regulatory cells in patients with celiac disease. J Clin Invest, 2008,118, 281-293.
7. Mazzarella G et al: Gliadin activates HLA class I-restricted CD8+ T cells in celiac disease intestinal
mucosa and induces the enterocyte apoptosis. Gastroenterology, 2008, 134, 1017-1027.
8. Fina D et al: Regulation of gut inflammation and Th17 cell response by interleukin-21. Gastroenterology,
2008, 134, 1038-1048.
9. Fina D et al: Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease.
Gut, 2008, 57, 887-892.
10. Agostoni C et al: Complementary feeding: a commentary by the ESPGHAN Committee on Nutrition.
J Pediatr Gastroenterol Nutr, 2008, 6, 99-110.
11. Troncone R et al: Rotavirus and celiac disease: clues to the pathogenesis and perspectives on prevention.
J Pediatr Gastroenterol Nutr, 2007, 44, 527-528.
12. Santaolalla R et al: Diagnostic value of duodenal antitissue transglutaminase antibodies in gluten-sensitive
enteropathy. Aliment Pharmacol Ther, 2008, 27, 820-829.
13. Tittanen M et al: Infiltration of Foxp3 espressing cells in jejunal mucosa in celiac disease but not in type
1 diabetes. Clin Exp Immunol, 2008,152,498-507.
14. Luopajärvi K et al: Enhanced levels of cow’s milk antibodies in infancy in children who develop type
1 diabetes later in childhood. Pediatr Diabetes, 2008, epub.
15. Sapone A et al: Zonulin upregulation is associated with increased gut permeability in subjects with type
1 diabetes and their relatives. Diabetes, 2006, 55, 1443-1449.
16. Hänninen A et al: Islet beta-cell-specific T-cells can use different homing mechanisms to infiltrate and
destroy pancreatis islets. Am J Pathol 2007, 170, 240-250.
17. Lee J et al: The “polarizing-tolerizing” mechanism of intestinal epithelium: its relevance to colonic
homeostasis. Semin Immunopathol, 2008, 30, 3-9.
18. Cario E et al: Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function.
Gastroenterology, 2007, 132, 1359-1374.
19. Brugman S et al: Antibiotic treatment partially protects against type I diabetes in the Bio-Breeding
diabetes-prone rat. Is the gut flora involved in the development of type I diabetes? Diabetologia,
2006, 49, 2105-2108.
20. Graham KL et al: Rotavirus infection accelerates type I diabetes in mice with established insulitis.
J Virol, 2008,82, 6139-49.
21. Oikarinen M et al: Detection of enteroviruses in the intestine of type I diabetic patients. Clin Exp
Immunol 2008, 151, 71-75.
22. Vaarala O.: Is it dietary insulin? Ann N Y Acad Sci, 2006, 1079, 350-359.
23. Santiago IL et al:Association of MYO9B haplotype with type I. diabetes. Hum Immunol 2008, 69, 112-115.
24. Zipitis CS et al: Vitamin D supplementation in early childhood and risk of type I diabetes: a systemic
review and meta-analysis. Arch Dis Child 2008, 93, 512-517.
25. Kong J et al: Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal
barrier. Am J Physiol Gastrointest Liver Physiol 2008, 294, G208-G216.
26. Kang SG et al: Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells. J Immunol,
Gastro 2009.qxd 5/9/2009 1:42 PM Page 475
476 Gastro Update 2009
2007,179, 3724-3733.
27. Mora JR: Homing imprinting and immunomodulation in the gut: role of dendritic cells and retinoids.
Inflamm Bowel Dis 2008, 14, 275-289.
28. Zeuthen LH et al: Toll-like receptor 2 and nuclear-binding oligomerization domain-2 play divergent
roles in the recognition of gut-derived lactobacilli and bifidobacteria in dendritic cells. Immunology,
2008, 123, 197-208.
29. Loh G et al: The toll-like receptors TLR2 and TLR4 do not affect the intestinal microbiota composition
in mice. Environ Microbiol 2008, 10, 709-715.
30. Edelman SM, Kasper DL: Symbiotic commensal bacteria direct maturation of the host immune system.
Curr Opin Gastroenterol, 2008, 24, 720-724.
31. Cho JH: The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol.
2008, 8, 458-466.
32. Mizoguchi A et al: Inflammatory bowel disease, past, present and future: lessions from animal models
J Gastroenterol, 2008, 43, 1-17.
33. Wildin RS et al.: Clinical and molecular features of the immunodysregulation polyendocrinopathy,
enteropathy, X-linked (IPEX) syndrome. J Med Genet 2002, 39, 537-545.
34. Sun CM et al: Small intestine lamina propria dendritic cells promote de novo generation of FoxP3 Treg
cells via retinoic acid. J Exp Med, 2007, 204, 1775-1785.
35. Tran DO et al: Induction of FOXP3 expression in naive human CD4+FOXP3+ T cells by T-cell receptor
stimulation is tranforming gowth factor beta dependent but does not confer a regulatory phenotype.
Blood 2007, 110, 2983-2990.
36. Bopp T et al: Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated
supression J Exp Med 2007, 204, 1303-1310.
37. Pandiyan P et al: CD4+CD25+FoxP3+ regulatory T cells induce cytokine deprivation-mediated apoptosis
of effector CD4+ T cells. Nat Immunol, 2007, 8, 1353-1362.
38. Collison LW et al: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007,
450, 566-569.
39. Boden EK, Snapper SB: Regulatory T cells in inflammatory bowel disease Curr Opin Gastroenterol,
2008, 24, 733-741.
40. Saruta M et al: Characterization of FoxP3+CD4+ regulatory T cells in Crohn’s disease. Clin Immunol,
2007, 125, 281-290.
41. Ricciardelli I et al: Anti tumour necrosis-alpha therapy increases the number of FOXP3+ regulatory T
cells in children affected by Crohn’s disease. Immunology 2008 16 Apr (epub ahead of print).
42. Plevy S et al: A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe
steroid-refractory ulcerativ colitis. Gastroenterology, 2007, 133, 1414-1422.
43. Perruche S et al: CD3-specific antibody-induced immune tolerance involves transforming growth
factor-beta from phagocytes digesting apoptotic T cells Nat Med, 2008, 14, 528-535.
44. Ruemelle FM et al: Clinical and molecular aspects of autoimmun enteropathy and immune dysregulation,
polyendocrinopathiy autoimmun enteropathy X-linked syndroma, Curr Opin Gastroenterol 2008, 24,
742-748.
45. Ardesjö B et al: Immunoreactivity against goblet cells in patients with inflammatory bowel disease.
Inflamm Bowel dis, 2008, 14, 652-661.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 476
Egyéb 477
46. Rao A et al: Successful bone marrow transplantation for IPEX syndrome after reduced-intensity
conditioning. Blood, 2007, 109, 383-385.
47. Ward RL: Rotavirus vaccines: how they work or don’t work. Expert Rev Mol Med, 2008, 10, 5.
48. Mestecky J et al: Oral immunization: an update. Curr Opin Gastroenterol, 2008, 24, 713-719.
